155 related articles for article (PubMed ID: 8970672)
1. Risks and synergies from drug interactions.
Sahai J
AIDS; 1996 Nov; 10 Suppl 1():S21-5. PubMed ID: 8970672
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.
Barry M; Mulcahy F; Merry C; Gibbons S; Back D
Clin Pharmacokinet; 1999 Apr; 36(4):289-304. PubMed ID: 10320951
[TBL] [Abstract][Full Text] [Related]
3. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
Joly V; Yeni P
Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
[TBL] [Abstract][Full Text] [Related]
4. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
5. HIV treatment options.
Smith D
AIDS Treat News; 1998 May; (No 294):4-5. PubMed ID: 11365404
[TBL] [Abstract][Full Text] [Related]
6. Standard treatments for HIV, Spring 1997.
Smith D
AIDS Treat News; 1997 Apr; (No 269):4-5. PubMed ID: 11364255
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.
Kirk O; Lundgren JD; Pedersen C; Mathiesen LR; Nielsen H; Katzenstein TL; Obel N; Gerstoft J
Antivir Ther; 2003 Dec; 8(6):595-602. PubMed ID: 14760893
[TBL] [Abstract][Full Text] [Related]
8. Understanding the reverse transcriptase inhibitors in HIV.
Edmonds-Ogbuokiri J
Fac Notes (New Orleans La); 1998; 10(6):13-5. PubMed ID: 11366142
[TBL] [Abstract][Full Text] [Related]
9. Antiretroviral therapies.
Owen WF
Clin Podiatr Med Surg; 1998 Apr; 15(2):227-39. PubMed ID: 9576051
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
11. Protease inhibitors at a glance...
Notes Undergr; 1998-1999 Winter; (No 38):suppl 1-4. PubMed ID: 11366198
[TBL] [Abstract][Full Text] [Related]
12. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
Joly V; Descamps D; Yeni P
AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447
[TBL] [Abstract][Full Text] [Related]
13. Drug interactions, toxicities, dosages: trials and tribulations and cocktails.
Crit Path AIDS Proj; 1998; (No 33):9-17. PubMed ID: 11366377
[TBL] [Abstract][Full Text] [Related]
14. Identification of potential clinically significant drug interactions in HIV-infected patients: a comprehensive therapeutic approach.
Iniesta-Navalón C; Franco-Miguel JJ; Gascón-Cánovas JJ; Rentero-Redondo L
HIV Med; 2015 May; 16(5):273-9. PubMed ID: 25523089
[TBL] [Abstract][Full Text] [Related]
15. Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine.
Crauwels H; van Heeswijk RP; Stevens M; Buelens A; Vanveggel S; Boven K; Hoetelmans R
AIDS Rev; 2013; 15(2):87-101. PubMed ID: 23681436
[TBL] [Abstract][Full Text] [Related]
16. Pharmacology of antiretroviral drugs.
Hoetelmans RM
Antivir Ther; 1999; 4 Suppl 3():29-41. PubMed ID: 16021869
[TBL] [Abstract][Full Text] [Related]
17. [Anti-HIV drugs].
Raffi F
Rev Prat; 1999 Oct; 49(16):1763-71. PubMed ID: 10578607
[TBL] [Abstract][Full Text] [Related]
18. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
[TBL] [Abstract][Full Text] [Related]
19. Double jeopardy: the hazards of drug-drug interactions.
Flexner C
Res Initiat Treat Action; 1998 Dec; 4(7):3-8. PubMed ID: 11366084
[TBL] [Abstract][Full Text] [Related]
20. The choice of HIV protease inhibitor: indinavir is currently the best option.
Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
